VolitionRx is a multinational epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid and is an indication that disease is present. VolitionRx is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
In this video, chief executive officer Cameron Reynolds discusses the company’s Q121 financial and operational results. In the quarter, VolitionRx secured its strongest-ever balance sheet, with approximately $33.1m in cash, strengthened its leadership team to drive commercial focus, expanded its intellectual property portfolio, initiated production of product components at scale at its Silver One facility, published three clinical papers, and continued its focus on product launches and licensing in both the human and veterinary spaces.